C.R. Bard Company Profile (NYSE:BCR)

C.R. Bard trades on the New York Stock Exchange (NYSE) under the ticker symbol "BCR."

C.R. Bard declared a quarterly dividend on Wednesday, October 11th. Shareholders of record on Friday, December 8th will be paid a dividend of $0.26 per share on Friday, December 29th. This represents a $1.04 annualized dividend and a yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 7th. View C.R. Bard's Dividend History.

C.R. Bard, Inc. (NYSE:BCR) posted its quarterly earnings results on Thursday, July, 27th. The company reported $2.92 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.84 by $0.08. The company had revenue of $979.70 million for the quarter, compared to analyst estimates of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The business's revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.54 earnings per share. View C.R. Bard's Earnings History.

C.R. Bard updated its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $11.70-$11.90 for the period, compared to the Thomson Reuters consensus estimate of $11.81.

7 brokerages have issued 1 year target prices for C.R. Bard's shares. Their forecasts range from $245.00 to $317.00. On average, they anticipate C.R. Bard's stock price to reach $282.29 in the next year. View Analyst Ratings for C.R. Bard.

Here are some recent quotes from research analysts about C.R. Bard stock:

• 1. According to Zacks Investment Research, "Over the past one year, C. R. Bard has outperformed the broader industry trends with respect to price performance. The company exhibited a solid second quarter of 2017, beating the Zacks Consensus on both lines. Looking forward C. R. Bard is expected to benefit from the impending merger with Becton, Dickinson and Company, especially in the areas of medication management and infection prevention. The $24 billion transaction is expected to close in the fourth quarter of 2017. We believe the development will provide benefits to the combined entity and bolster its foothold in the global medical devices market. The growing adoption of Lutonix DCB is also expected to drive top-line growth in the coming quarters.However, a challenging Med-tech environment is a major concern. The company witnesses significant pricing pressure as well. Additionally, cutthroat competition in the hernia fixation and peripheral stent businesses are likely to dent growth." (8/1/2017)
• 2. Needham & Company LLC analysts commented, "BCR’s 4Q16 revenue and EPS beat consensus and management provided initial 2017 revenue guidance that was in line with consensus and EPS guidance that was above consensus. Organic revenue growth improved to 6.9% in 4Q16 from 6.4% in 3Q16. Although BCR’s gross margin declined slightly, its operating margin improved by 150 bps Y/Y due to significant SG&A leverage." (1/27/2017)

Some companies that are related to C.R. Bard include Baxter International (BAX), Zimmer Biomet Holdings (ZBH), Align Technology (ALGN), DENTSPLY SIRONA (XRAY), Steris Plc (STE), West Pharmaceutical Services (WST), Bio-Rad Laboratories (BIO), Hill-Rom Holdings (HRC), VWR Corporation (VWR), Integra Lifesciences Holdings Corp (IART), DexCom (DXCM), ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), NuVasive (NUVA), Nevro Corp. (NVRO), Haemonetics Corporation (HAE) and Halyard Health (HYH).

C.R. Bard's management team includes the folowing people:

• Timothy M. Ring, Chairman of the Board, Chief Executive Officer
• John H. Weiland, President, Vice Chairman of the Board, Chief Operating Officer
• James C. Beasley, Group President
• Timothy P. Collins, Group President
• John P. Groetelaars, Group President
• Christopher S. Holland, Chief Financial Officer, Senior Vice President
• Samrat S. Khichi, Senior Vice President, General Counsel, Secretary
• John A. DeFord Ph.D., Senior Vice President - Science, Technology and Clinical Affairs
• Frank Lupisella Jr., Vice President, Controller
• Betty D. Larson, Vice President - Human Resources

C.R. Bard's stock is owned by a variety of of institutional and retail investors. Top institutional investors include APG Asset Management N.V. (0.61%), Havens Advisors LLC (0.03%), State Treasurer State of Michigan (0.03%), Harvey Investment Co. LLC (0.02%), LS Investment Advisors LLC (0.02%) and Meeder Asset Management Inc. (0.01%). Company insiders that own C.R. Bard stock include Anthony Welters, Betty D Larson, Christopher S Holland, Frank Lupisella Jr, Frank Lupisella, Jr, Gail K Naughton, Jim C Beasley, John A Deford, John H Weiland, John P Groetelaars, Patricia G Christian, Sharon M Luboff, Timothy M Ring, Timothy P Collins, Tommy G Thompson and Tony L White. View Institutional Ownership Trends for C.R. Bard.

C.R. Bard's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Robeco Institutional Asset Management B.V., State Treasurer State of Michigan, Meeder Asset Management Inc., Harvey Investment Co. LLC, LS Investment Advisors LLC, Park National Corp OH and Foster & Motley Inc.. Company insiders that have sold C.R. Bard stock in the last year include Betty D Larson, Christopher S Holland, Frank Lupisella Jr, Frank Lupisella, Jr, Gail K Naughton, Jim C Beasley, John A Deford, John H Weiland, John P Groetelaars, Sharon M Luboff, Timothy M Ring and Timothy P Collins. View Insider Buying and Selling for C.R. Bard.

C.R. Bard's stock was bought by a variety of institutional investors in the last quarter, including Havens Advisors LLC, Assenagon Asset Management S.A., Oakbrook Investments LLC and Curbstone Financial Management Corp. View Insider Buying and Selling for C.R. Bard.

Shares of C.R. Bard can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of C.R. Bard stock can currently be purchased for approximately $330.16.